At ESMO 2023, pharmaceutical companies like Daiichi Sankyo, AstraZeneca, Revolution Medicines, Jacobio Pharma, Merus, Merck, Mirati, Sichuan Baili Pharmaceutical, and more are on the edge of their seats, ready to unveil groundbreaking research on NSCLC in oral and poster presentations. Let’s have a look at the exciting EGFR×HER3-targeting ADC developed by SystImmune/Sichuan Baili Pharmaceutical for NSCLC!

NSCLC Highlights

• Abstract Number – #1316MO
• Abstract Type – Mini Oral Session
• Indication – NSCLC
• Target –  EGFR×HER3

Due to their overexpression and pathway dependence in human epithelial carcinoma tumors, EGFR and HER3 are targeted in cancer therapy. To develop a promising therapeutic antitumor agent, SystImmune is currently developing BL-B01D1, an ADC targeting both EGFR and HER3. It can bind to EGFR and/or HER3-positive cells and shows stronger tumor inhibition capacities than individual anti-EGFR and anti-HER3 ADCs. It comprises a bispecific antibody against EGFR/HER3 (SI-B001), a cathepsin B cleavable linker, and a novel topoisomerase I inhibitor agent (Ed-04), derived from the alkaloid camptothecin. 

The preclinical studies have unveiled the remarkable potential of BL-B01D1, indicating its promise as a novel therapeutic option across a wide spectrum of human cancers. Progress in the clinical Phase I trials has shown impressive efficacy, accompanied by minimal targeted toxicity, especially in the context of treating NSCLC. As of March 2023, the drug achieved an overall response rate (ORR) of 63.2% for the EGFRmut group and the disease control rate (DCR) was approximately 89.5% for the same with acceptable safety profiles. The available data suggest that BL-B01D1 could emerge as a groundbreaking therapeutic agent for NSCLC.

In this upcoming ESMO session, the company is anticipated to discuss more on this study and provide further updates regarding DoR, mPFS, and others.

Note: The therapeutics segment is experiencing significant NSCLC clinical trial activity, which is further expected to drive Non-Small Cell Lung Caner market growth in the coming years.